As global markets experience broad-based gains with smaller-cap indexes outperforming large-caps, investors are closely watching the Federal Reserve's upcoming decisions on interest rates amid a strong U.S. labor market and rising home sales. In this environment, identifying high growth tech stocks involves focusing on companies that can capitalize on technological advancements and maintain robust performance despite geopolitical tensions and economic uncertainties.
Top 10 High Growth Tech Companies
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Material Group | 20.45% | 24.01% | ★★★★★★ |
Pharma Mar | 25.97% | 56.89% | ★★★★★★ |
Ascelia Pharma | 76.15% | 47.16% | ★★★★★★ |
Waystream Holding | 22.46% | 109.25% | ★★★★★★ |
JNTC | 20.52% | 57.26% | ★★★★★★ |
TG Therapeutics | 34.66% | 56.48% | ★★★★★★ |
Elliptic Laboratories | 65.73% | 103.55% | ★★★★★★ |
Alkami Technology | 21.89% | 98.60% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.45% | 70.66% | ★★★★★★ |
Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
Click here to see the full list of 1300 stocks from our High Growth Tech and AI Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Valneva (ENXTPA:VLA)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet needs, with a market cap of €332.86 million.
Operations: Valneva SE generates revenue primarily through the development, manufacturing, and commercialization of vaccines targeting infectious diseases with significant unmet needs. The company's focus on prophylactic vaccines positions it within a niche market segment in the pharmaceutical industry.
Valneva has shown a remarkable turnaround with its recent earnings, posting a net income of €24.74 million for the nine months ended September 2024, a significant shift from a net loss of €69.27 million in the previous year. This financial recovery is underscored by an impressive 24.6% increase in revenue year-over-year. The company's commitment to innovation is evident in its R&D efforts, which are strategically aligned with addressing global health threats like shigellosis and chikungunya; diseases that currently lack effective vaccines. Valneva's R&D expenses have been pivotal, enabling them to advance their pipeline significantly and secure Fast Track designation from the FDA for their lead vaccine candidate S4V2, highlighting its potential to meet urgent medical needs worldwide.
- Dive into the specifics of Valneva here with our thorough health report.
Evaluate Valneva's historical performance by accessing our past performance report.
Better Collective (OM:BETCO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Better Collective A/S is a digital sports media company operating in Europe, North America, and internationally with a market cap of SEK8.18 billion.
Operations: The company generates revenue primarily through its Publishing and Paid Media segments, with Publishing contributing €252.96 million and Paid Media €107.54 million.
Despite a challenging market, Better Collective's strategic focus on R&D has positioned it for potential future growth. In 2024, the company allocated significant resources to innovation, with R&D expenses reaching €53.2 million, underlining its commitment to advancing its technological capabilities in the highly competitive online gaming sector. This investment represents a substantial portion of revenue, evidencing a robust approach to harnessing emerging technologies and maintaining competitiveness. However, recent financial adjustments reflect market realities; revenue forecasts were revised down to between €355 million and €375 million from previous higher estimates due to unforeseen pressures. Nonetheless, with earnings expected to grow by 53.2% annually, Better Collective remains an intriguing prospect in its niche of digital sports betting platforms.
Storytel (OM:STORY B)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Storytel AB (publ) offers streaming services for audiobooks and e-books and has a market capitalization of approximately SEK4.72 billion.
Operations: Storytel AB (publ) generates revenue primarily from its streaming services for audiobooks and e-books, with the Books segment contributing SEK859.34 million. The company also records a Segment Adjustment of SEK3.51 billion, reflecting internal financial adjustments within its operations.
Amidst a transformative phase, Storytel has demonstrated resilience and strategic acumen, particularly in its R&D endeavors. In 2024, the company's R&D expenses were notably high, underlining its commitment to innovation and staying relevant in the competitive media industry. This investment is crucial as it aligns with Storytel's impressive revenue growth of 9.4% per year and an anticipated profit surge of 99.1% annually. Additionally, the recent partnership with Wellhub signals strategic market expansion, potentially boosting subscriber numbers across diverse geographies by integrating audiobooks into wellness programs—a move that could significantly influence future earnings trajectories while enhancing brand visibility and user engagement globally.
- Delve into the full analysis health report here for a deeper understanding of Storytel.
Gain insights into Storytel's historical performance by reviewing our past performance report.
Next Steps
- Delve into our full catalog of 1300 High Growth Tech and AI Stocks here.
- Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About OM:STORY B
High growth potential with adequate balance sheet.